Growth Metrics

Eli Lilly (LLY) Other Non-Current Liabilities (2016 - 2025)

Eli Lilly's Other Non-Current Liabilities history spans 17 years, with the latest figure at $5.9 billion for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities rose 68.87% year-over-year to $5.9 billion; the TTM value through Dec 2025 reached $5.9 billion, up 68.87%, while the annual FY2025 figure was $5.9 billion, 68.87% up from the prior year.
  • Other Non-Current Liabilities reached $5.9 billion in Q4 2025 per LLY's latest filing, up from $3.8 billion in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.9 billion in Q4 2025 to a low of $1.6 billion in Q4 2021.
  • Average Other Non-Current Liabilities over 5 years is $3.2 billion, with a median of $3.5 billion recorded in 2024.
  • Peak YoY movement for Other Non-Current Liabilities: tumbled 52.3% in 2022, then skyrocketed 129.87% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $1.6 billion in 2021, then grew by 10.93% to $1.8 billion in 2022, then soared by 111.03% to $3.8 billion in 2023, then decreased by 9.62% to $3.5 billion in 2024, then soared by 68.87% to $5.9 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Other Non-Current Liabilities are $5.9 billion (Q4 2025), $3.8 billion (Q3 2025), and $5.7 billion (Q2 2025).